ABPI and Birmingham Health Partners collaborate on health challenges

abpi-logoThe Association of the British Pharmaceutical Industry (ABPI) and Birmingham Health Partners (BHP) have formed a partnership in order to “tackle the biggest health challenges” within Birmingham.

The partnership, which will focus on West Midlands’ six million residents, will utilise real-time clinical trials and health data to accelerate research and improve cancer care, maternity services, child health, obesity, and dementia.

The team, founded on a Memorandum of Understanding, has stated aims to make Birmingham a world leader in the development of precision medicines tailored to patients based on genetic, environmental and lifestyle factors.

Dubbed the Birmingham Health Partners & Industry Steering Group (BHPISG), the collaboration will play to Birmingham’s strengths in healthcare data, digitalisation of health care services, genomic medicine, diagnostics and clinical trials and will help address the biggest challenges facing the city and region.

Challenges it plans to tackle include improving cancer outcomes, addressing maternal and paediatric health, tackling multimorbidity in an ageing population and improving NHS care by matching patient results with ongoing research.

Andy Street, mayor of the West Midlands stated that with a diverse population of nearly six million citizens, the West Midlands is the “ideal place to develop and test new innovations in healthcare, such as precision medicines tailored to individual patient needs”

He continued, “This exciting agreement will bring world-class researchers, healthcare practitioners and industry together to tackle the big health challenges facing our region and help deliver on our West Midlands Local Industrial Strategy.

“It also demonstrates the strength of the West Midlands life sciences cluster, which is rapidly emerging as a flagship location for developing and testing innovations in healthcare.”

The four challenge focuses were chosen because they have national or international relevance and can be scaled up if successful.

Source: PharmaTimes